General Electric's Healthcare Investor day highlighted the company's diversified global healthcare portfolio that could remain well positioned to contribute to growth over time despite a lower growth profile following the pending sale of BioPharma, Citi analyst Andrew Kaplowitz tells investors in a research note. GE's near- to mid-term financial outlook for the business of low to mid-single digit revenue grow, 25 to 75 basis points of annual margin expansion, and 85%-95% free cash flow conversion are supportive of good earnings and cash contribution from the business going forward, adds the analyst. He keeps a Buy rating on shares of General Electric.

Citi raised the firm's price target on GE Aerospace to $186 from $120.43 and keeps a Buy rating on the shares. The company's' Q1 was better than expected and it modestly increased its full-year EBIT outlook, the analyst tells investors in a research note. The firm says commercial aftermarket demand remains robust.

BofA analyst Ronald Epstein raised the firm's price target on GE Aerospace to $180 from $165 and keeps a Buy rating on the shares. GE boasts a unique portfolio with exposure across aircraft manufacturers, aircraft classes, legacy/new/nextgen platforms, and aftermarket/OE customers, says the firm, which believes GE is "strongly positioned to benefit from secular commercial aero growth."